244 related articles for article (PubMed ID: 33611636)
1. Real-world analysis of clinicopathological characteristics, survival rates, and prognostic factors in patients with melanoma brain metastases in China.
Wang Y; Lian B; Si L; Chi Z; Sheng X; Wang X; Mao L; Tang B; Li S; Yan X; Bai X; Zhou L; Cui C; Guo J
J Cancer Res Clin Oncol; 2021 Sep; 147(9):2731-2740. PubMed ID: 33611636
[TBL] [Abstract][Full Text] [Related]
2. Combined immunotherapy with nivolumab and ipilimumab with and without local therapy in patients with melanoma brain metastasis: a DeCOG* study in 380 patients.
Amaral T; Kiecker F; Schaefer S; Stege H; Kaehler K; Terheyden P; Gesierich A; Gutzmer R; Haferkamp S; Uttikal J; Berking C; Rafei-Shamsabadi D; Reinhardt L; Meier F; Karoglan A; Posch C; Gambichler T; Pfoehler C; Thoms K; Tietze J; Debus D; Herbst R; Emmert S; Loquai C; Hassel JC; Meiss F; Tueting T; Heinrich V; Eigentler T; Garbe C; Zimmer L;
J Immunother Cancer; 2020 Mar; 8(1):. PubMed ID: 32221017
[TBL] [Abstract][Full Text] [Related]
3. Clinical outcomes of melanoma brain metastases treated with stereotactic radiosurgery and anti-PD-1 therapy, anti-CTLA-4 therapy, BRAF/MEK inhibitors, BRAF inhibitor, or conventional chemotherapy.
Ahmed KA; Abuodeh YA; Echevarria MI; Arrington JA; Stallworth DG; Hogue C; Naghavi AO; Kim S; Kim Y; Patel BG; Sarangkasiri S; Johnstone PA; Sahebjam S; Khushalani NI; Forsyth PA; Harrison LB; Yu M; Etame AB; Caudell JJ
Ann Oncol; 2016 Dec; 27(12):2288-2294. PubMed ID: 27637745
[TBL] [Abstract][Full Text] [Related]
4. The combination of stereotactic radiosurgery with immune checkpoint inhibition or targeted therapy in melanoma patients with brain metastases: a retrospective study.
Martins F; Schiappacasse L; Levivier M; Tuleasca C; Cuendet MA; Aedo-Lopez V; Gautron Moura B; Homicsko K; Bettini A; Berthod G; Gérard CL; Wicky A; Bourhis J; Michielin O
J Neurooncol; 2020 Jan; 146(1):181-193. PubMed ID: 31836957
[TBL] [Abstract][Full Text] [Related]
5. Impact of radiotherapy and sequencing of systemic therapy on survival outcomes in melanoma patients with previously untreated brain metastasis: a multicenter DeCOG study on 450 patients from the prospective skin cancer registry ADOREG.
Franklin C; Mohr P; Bluhm L; Grimmelmann I; Gutzmer R; Meier F; Garzarolli M; Weichenthal M; Pfoehler C; Herbst R; Terheyden P; Utikal J; Ulrich J; Debus D; Haferkamp S; Kaatz M; Forschner A; Leiter U; Nashan D; Kreuter A; Sachse M; Welzel J; Heinzerling L; Meiss F; Weishaupt C; Gambichler T; Weyandt G; Dippel E; Schatton K; Celik E; Trommer M; Helfrich I; Roesch A; Zimmer L; Livingstone E; Schadendorf D; Horn S; Ugurel S
J Immunother Cancer; 2022 Jun; 10(6):. PubMed ID: 35688555
[TBL] [Abstract][Full Text] [Related]
6. Toxicity and efficacy of Gamma Knife radiosurgery for brain metastases in melanoma patients treated with immunotherapy or targeted therapy-A retrospective cohort study.
Gatterbauer B; Hirschmann D; Eberherr N; Untersteiner H; Cho A; Shaltout A; Göbl P; Fitschek F; Dorfer C; Wolfsberger S; Kasprian G; Höller C; Frischer JM
Cancer Med; 2020 Jun; 9(11):4026-4036. PubMed ID: 32249551
[TBL] [Abstract][Full Text] [Related]
7. Improved survival of patients with melanoma brain metastases in the era of targeted BRAF and immune checkpoint therapies.
Sloot S; Chen YA; Zhao X; Weber JL; Benedict JJ; Mulé JJ; Smalley KS; Weber JS; Zager JS; Forsyth PA; Sondak VK; Gibney GT
Cancer; 2018 Jan; 124(2):297-305. PubMed ID: 29023643
[TBL] [Abstract][Full Text] [Related]
8. Stereotactic radiosurgery and anti-PD-1 + CTLA-4 therapy, anti-PD-1 therapy, anti-CTLA-4 therapy, BRAF/MEK inhibitors, BRAF inhibitors, or conventional chemotherapy for the management of melanoma brain metastases.
Dohm AE; Nakashima JY; Kalagotla H; Jiang SX; Tang JD; Bhandari M; Kim Y; Graham JA; Khushalani NI; Forsyth PA; Etame AB; Liu JK; Tran ND; Vogelbaum MA; Wuthrick EJ; Yu HM; Oliver DE; Ahmed KA
Eur J Cancer; 2023 Oct; 192():113287. PubMed ID: 37657227
[TBL] [Abstract][Full Text] [Related]
9. Melanoma brain metastasis presentation, treatment, and outcomes in the age of targeted and immunotherapies.
Bander ED; Yuan M; Carnevale JA; Reiner AS; Panageas KS; Postow MA; Tabar V; Moss NS
Cancer; 2021 Jun; 127(12):2062-2073. PubMed ID: 33651913
[TBL] [Abstract][Full Text] [Related]
10. Melanoma brain metastasis: the impact of stereotactic radiosurgery, BRAF mutational status, and targeted and/or immune-based therapies on treatment outcome.
Kotecha R; Miller JA; Venur VA; Mohammadi AM; Chao ST; Suh JH; Barnett GH; Murphy ES; Funchain P; Yu JS; Vogelbaum MA; Angelov L; Ahluwalia MS
J Neurosurg; 2018 Jul; 129(1):50-59. PubMed ID: 28799876
[TBL] [Abstract][Full Text] [Related]
11. Stereotactic radiosurgery and immunotherapy in melanoma brain metastases: Patterns of care and treatment outcomes.
Gabani P; Fischer-Valuck BW; Johanns TM; Hernandez-Aya LF; Keller JW; Rich KM; Kim AH; Dunn GP; Robinson CG; Chicoine MR; Huang J; Abraham CD
Radiother Oncol; 2018 Aug; 128(2):266-273. PubMed ID: 29960685
[TBL] [Abstract][Full Text] [Related]
12. Stereotactic radiosurgery combined with targeted/ immunotherapy in patients with melanoma brain metastasis.
Hadi I; Roengvoraphoj O; Bodensohn R; Hofmaier J; Niyazi M; Belka C; Nachbichler SB
Radiat Oncol; 2020 Feb; 15(1):37. PubMed ID: 32059731
[TBL] [Abstract][Full Text] [Related]
13. Impact of radiation, systemic therapy and treatment sequencing on survival of patients with melanoma brain metastases.
Rauschenberg R; Bruns J; Brütting J; Daubner D; Lohaus F; Zimmer L; Forschner A; Zips D; Hassel JC; Berking C; Kaehler KC; Utikal J; Gutzmer R; Terheyden P; Meiss F; Rafei-Shamsabadi D; Kiecker F; Debus D; Dabrowski E; Arnold A; Garzarolli M; Kuske M; Beissert S; Löck S; Linn J; Troost EGC; Meier F
Eur J Cancer; 2019 Mar; 110():11-20. PubMed ID: 30739835
[TBL] [Abstract][Full Text] [Related]
14. Upfront Surgical Resection of Melanoma Brain Metastases Provides a Bridge Toward Immunotherapy-Mediated Systemic Control.
Alvarez-Breckenridge C; Giobbie-Hurder A; Gill CM; Bertalan M; Stocking J; Kaplan A; Nayyar N; Lawrence DP; Flaherty KT; Shih HA; Oh K; Batchelor TT; Cahill DP; Sullivan R; Brastianos PK
Oncologist; 2019 May; 24(5):671-679. PubMed ID: 30796152
[TBL] [Abstract][Full Text] [Related]
15. Single institutional outcomes of whole brain radiotherapy for metastatic melanoma brain metastases.
Jiang C; Kleber TJ; Switchenko JM; Khan MK
Radiat Oncol; 2021 Feb; 16(1):31. PubMed ID: 33557890
[TBL] [Abstract][Full Text] [Related]
16. Impact on overall survival of the combination of BRAF inhibitors and stereotactic radiosurgery in patients with melanoma brain metastases.
Wolf A; Zia S; Verma R; Pavlick A; Wilson M; Golfinos JG; Silverman JS; Kondziolka D
J Neurooncol; 2016 May; 127(3):607-15. PubMed ID: 26852222
[TBL] [Abstract][Full Text] [Related]
17. BRAF V600E mutation and BRAF kinase inhibitors in conjunction with stereotactic radiosurgery for intracranial melanoma metastases.
Xu Z; Lee CC; Ramesh A; Mueller AC; Schlesinger D; Cohen-Inbar O; Shih HH; Sheehan JP
J Neurosurg; 2017 Mar; 126(3):726-734. PubMed ID: 27203149
[TBL] [Abstract][Full Text] [Related]
18. Treatment patterns and outcomes in BRAF V600E-mutant melanoma patients with brain metastases receiving vemurafenib in the real-world setting.
Gibney GT; Gauthier G; Ayas C; Galebach P; Wu EQ; Abhyankar S; Reyes C; Guérin A; Yim YM
Cancer Med; 2015 Aug; 4(8):1205-13. PubMed ID: 25991583
[TBL] [Abstract][Full Text] [Related]
19. Current Treatment of Melanoma Brain Metastasis.
Rishi A; Yu HM
Curr Treat Options Oncol; 2020 Apr; 21(6):45. PubMed ID: 32350685
[TBL] [Abstract][Full Text] [Related]
20. Efficacy of anti-PD-1 therapy in patients with melanoma brain metastases.
Parakh S; Park JJ; Mendis S; Rai R; Xu W; Lo S; Drummond M; Rowe C; Wong A; McArthur G; Haydon A; Andrews MC; Cebon J; Guminski A; Kefford RF; Long GV; Menzies AM; Klein O; Carlino MS
Br J Cancer; 2017 Jun; 116(12):1558-1563. PubMed ID: 28524161
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
